ACP
ABBV icon

Argyle Capital Partners’s AbbVie ABBV Stock Holding History

Argyle Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.34M Buy
9,306
+413
+5% +$88.9K 1.48% 14
2026
Q1 		$1.93M Sell
8,893
-4
-0% -$887 1.39% 17
2025
Q4 		$2.03M Sell
8,897
-577
-6% -$131K 1.49% 18
2025
Q3 		$2.19M Sell
9,474
-66
-0.7% -$13.4K 1.57% 11
2025
Q2 		$1.77M Sell
9,540
-114
-1% -$21.2K 1.46% 15
2025
Q1 		$2.02M Sell
9,654
-620
-6% -$121K 1.73% 13
2024
Q4 		$1.83M Buy
+10,274
New +$1.89M 1.57% 12

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Argyle Capital Partners's ABBV Position: Q2 2026 in Review

Argyle Capital Partners increased its AbbVie (ABBV) stake by 4.6% in Q2 2026, buying an estimated $88.9K and bringing the position to 9,306 shares worth $2.34M. The position accounts for 1.48% of the portfolio, ranked #14.

Argyle Capital Partners first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Argyle Capital Partners held 9,306 shares of AbbVie worth $2.34M as of Q2 2026.
  • Argyle Capital Partners bought 413 AbbVie shares in Q2 2026, an estimated $88.9K.
  • AbbVie made up 1.48% of Argyle Capital Partners's portfolio in Q2 2026, its #14 holding.
  • Argyle Capital Partners first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Argyle Capital Partners's 13F filing for Q2 2026, filed 7 Aug 2026.